Neuland Reports Strong FY26 Revenue And Margin Gains
ECONOMY & POLICY

Neuland Reports Strong FY26 Revenue And Margin Gains

Neuland Laboratories Limited reported annual results for the year ended 31 March 2026, with total income of Rs. 20,531 mn and EBITDA of Rs. 6,034 mn. The company said Q4FY26 revenue stood at Rs. 7,887 mn while Q4 EBITDA was Rs. 3,194 mn, reflecting strong sequential performance. Management noted robust operating leverage and improved margins during the fourth quarter.

EBITDA margin for Q4FY26 was 40.5 per cent, up from 17.3 per cent a year earlier, representing an increase of 2316 basis points. Profit before tax for the quarter was Rs. 2,870 mn and profit after tax was Rs. 2,125 mn. Year-on-year Q4 income rose 134.9 per cent while EBITDA increased 448.6 per cent and profit after tax grew 666.3 per cent.

The chief executive officer and managing director said the company had ended FY26 on a strong note and that business visibility was good in the short to medium term, anchored by commercial and near-commercial molecules. He said the company would focus on execution discipline, customer satisfaction and protection of business fundamentals while laying the groundwork for growth beyond the immediate horizon. Investments in peptide manufacturing and a new research and development centre were reported to be proceeding according to plan and business development efforts were being aligned to attract projects that support high quality, sustainable growth.

The company scheduled a one-hour earnings call at 17:30 IST on Tuesday, 12 May 2026, and said the transcript would be uploaded to the corporate website in due course. Neuland was described as a cGMP manufacturer with over four decades of experience, more than 300 developed processes, about 100 APIs and around 1000 regulatory filings across major jurisdictions, supported by multiple global certifications.

"Join industry leaders at RAHSTA Expo, India's premier platform for roads, highways and traffic infrastructure. Register now to explore innovations, network with experts and shape the future of mobility."

Neuland Laboratories Limited reported annual results for the year ended 31 March 2026, with total income of Rs. 20,531 mn and EBITDA of Rs. 6,034 mn. The company said Q4FY26 revenue stood at Rs. 7,887 mn while Q4 EBITDA was Rs. 3,194 mn, reflecting strong sequential performance. Management noted robust operating leverage and improved margins during the fourth quarter. EBITDA margin for Q4FY26 was 40.5 per cent, up from 17.3 per cent a year earlier, representing an increase of 2316 basis points. Profit before tax for the quarter was Rs. 2,870 mn and profit after tax was Rs. 2,125 mn. Year-on-year Q4 income rose 134.9 per cent while EBITDA increased 448.6 per cent and profit after tax grew 666.3 per cent. The chief executive officer and managing director said the company had ended FY26 on a strong note and that business visibility was good in the short to medium term, anchored by commercial and near-commercial molecules. He said the company would focus on execution discipline, customer satisfaction and protection of business fundamentals while laying the groundwork for growth beyond the immediate horizon. Investments in peptide manufacturing and a new research and development centre were reported to be proceeding according to plan and business development efforts were being aligned to attract projects that support high quality, sustainable growth. The company scheduled a one-hour earnings call at 17:30 IST on Tuesday, 12 May 2026, and said the transcript would be uploaded to the corporate website in due course. Neuland was described as a cGMP manufacturer with over four decades of experience, more than 300 developed processes, about 100 APIs and around 1000 regulatory filings across major jurisdictions, supported by multiple global certifications.

Next Story
Real Estate

Pecan Realty Completes Rs 1.5 Billion Transactions

Pecan Realty has recently completed four institutional transactions worth over Rs 1.5 billion over the past two years, strengthening its position as an execution-led real estate platform. The deals include resolution-led acquisitions, structured finance transactions and capital partnerships across its development portfolio.The transactions covered acquisitions through the National Company Law Tribunal process and helped provide repayment or exits to both private and public sector lenders. The company said the deals demonstrate its ability to resolve complex project situations, work with instit..

Next Story
Real Estate

SNN Estates Expands North Bengaluru Housing Project

SNN Estates has announced an expansion of its SNN Estates Felicity residential project in North Bengaluru following strong buyer demand, with 75 per cent of the first-phase inventory sold within three days of launch.The developer will add 76 apartments in the new phase, taking the project's estimated revenue potential to around Rs 1,000 crore upon completion of Phase 2.Spread across 6.5 acres in Rachenahalli, near Manyata Tech Park, the project comprises 604 apartments in 1.5, 2, 2.5, 3 and 4 BHK configurations. The development includes a 50,000-sq-ft clubhouse with amenities such as sports co..

Next Story
Infrastructure Urban

SCG Drives ASEAN Industrial Transformation Strategy

SCG is strengthening its focus on ASEAN as a key growth region by advancing industrial transformation, enhancing competitiveness and building resilient regional value chains. Thammasak Sethaudom, President and Chief Executive Officer, SCG, highlighted the need for industries to continuously develop capabilities, strengthen resilience and deepen regional cooperation to achieve sustainable long-term growth.SCG views ASEAN as an important growth engine alongside China, supported by favourable demographics, trade connectivity and investment flows. With ASEAN’s GDP projected to grow by around 4.7..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement